908 DevicesMASS +2.87%70 EBITDA Margin % is -48.60% as of Mar. 2026. GuruFocus rates MASS with a GF Score™ of 70/100 and a GF Value™ of $6.91 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 816 Medical Devices & Instruments companies, 908 Devices ranks worse than 75.74% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. 908 Devices's EBITDA for the
three
months ended in Mar. 2026 was $-6.50 Mil. 908 Devices's Revenue for the
three
months ended in Mar. 2026 was $13.38 Mil. Therefore, 908 Devices's EBITDA margin for the quarter that ended in Mar. 2026 was -48.60%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
908 Devices EBITDA Margin % Related Terms
908 Devices EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for 908 Devices's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 908 Devices's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
908 Devices EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where 908 Devices's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
908 Devices (MASS) has a EBITDA Margin % of -48.60% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 908 Devices and its competitors. According to the industry distribution chart, 908 Devices ranks #618 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 75.7%.
Is 908 Devices' EBITDA Margin % too high?
908 Devices' current EBITDA Margin % is -48.60%. Based on the distribution chart, 908 Devices ranks #618 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 908 Devices has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 908 Devices' EBITDA Margin % compare to ELMD and SI?
According to the Medical Devices & Instruments industry distribution chart, 908 Devices ranks #618 out of 816 companies for EBITDA Margin %. This places 908 Devices in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 908 Devices and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 908 Devices's current EBITDA Margin % is -48.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 908 Devices stock overvalued right now?
Based on GuruFocus' analysis, 908 Devices (MASS) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $8.98 — trading 30% above its estimated fair value. The current EBITDA Margin % is -48.60%. 908 Devices' overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 908 Devices (MASS), the current EBITDA Margin % is -48.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 908 Devices (MASS) Overvalued in 2026?
Based on GuruFocus' analysis, 908 Devices stock appears to be overvalued.
The current stock price of $8.98 is trading 30% above its estimated GF Value™ of $6.91.
GuruFocus considers 908 Devices to be Modestly Overvalued.
Key valuation signals for MASS:
EBITDA Margin %: -48.60%
GF Value™: $6.91 vs. price of $8.98 (30% above fair value)
No single metric tells the full story. See the MASS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
70GF Score
Get the complete analysis for MASS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MASS has been successfully added to your 
